Company: IPHYF
Filing Date: 2025-04-30
Form Type: 20-F
Source: 0001598599-25-000042
Chunk: 38

Company: Innate Pharma SA
Filing Date: 2025-04-30
Form: 20-F
Item: Item 3
Chunk 38
---
 to be profitable in the future will depend on its ability to generate revenue from sales relating to its product candidates, if approved, and its ability to obtain regulatory approval for marketing its product candidates. If its product candidates receive regulatory approval, its future revenues will depend upon the size of any markets in which its product candidates have received approval, and

market acceptance, reimbursement from third-party payors and market share. Any of these factors could have a material adverse effect on Innate's business, prospects, financial condition and results of operations.

The Company may need to raise additional funding to complete the development and any commercialization of its product candidates, which may not be available on acceptable terms, or at all, and failure to obtain this necessary capital when needed may force it to delay, limit or terminate its product development efforts or other operations.

Innate is currently advancing its product candidates through preclinical and clinical development, and anticipates relying on partners as the Company advances them. Innate currently retains the full development and marketing rights to lacutamab, IPH5301, IPH6501 and IPH4502, and may retain rights to additional proprietary product candidates in the future. The development of immunotherapy product candidates is expensive, and Innate expects its research and development expenses to increase as the Company advances its product candidates through clinical studies and regulatory approvals. If clinical studies are successful and if Innate obtains regulatory approval for product candidates that the Company develops, Innate expects to incur commercialization expenses before these product candidates are marketed and sold.

The Company anticipates that its expenses will increase substantially if and as it:

• continues its research, preclinical and clinical development of its product candidates if its current collaboration partners cease their collaborations with us;

• expands the scope of its current clinical studies for its product candidates;

• initiates additional preclinical, clinical or other studies for its product candidates;

• further develops manufacturing processes for its product candidates;

• changes or adds additional manufacturers or suppliers;

• seeks regulatory and marketing authorizations for its product candidates that successfully complete clinical studies;

• establishes a sales, marketing and distribution infrastructure to commercialize any product for which the Company may obtain marketing authorization;

• seeks to identify and validate additional product candidates that may result in additional preclinical, clinical or other product studies;

• acquires or in-license agreements or other product candidates and technologies;

• makes milestone or other payments under any in-license agreements;

• maintains, protects, defends and expands its intellectual property portfolio;

• attracts and retains new and existing skilled personnel;

•